GE医疗发布密歇根大学关于End-tidal Control麻醉软件的回顾性真实世界研究，无新增商业或监管事实

University of Michigan
iv
evaluating the use of
End-tidal Control software
across a large multisite academic health system in
Anesthesia & Analgesia Practice
.
The retrospective observational study analyzed 12,818 adult general anesthesia cases performed at
University of Michigan Health
–
Ann Arbor
locations between
April 1, 2023
and
September 30, 2024
on anesthesia machines with End-tidal Control software.
The study found End-tidal Control was used in 6,755 cases (52.7%) and its use was associated with:
62.3% reduction
in median fresh gas flow during maintenance of anesthesia
39.3% reduction
in sevoflurane consumption
“Health systems are looking for practical ways to support clinicians while advancing more sustainable care,” said
John Beard
, MD, anesthesiologist and Chief Medical Officer of Patient Care Solutions at
GE HealthCare
. “This research at the
University of Michigan
adds important real-world evidence of End-tidal Control use at scale and how it may help reduce fresh gas flows and anesthetic agent consumption.”
End-tidal Control software supports the clinician in maintaining clinician-set targets for end-tidal anesthetic agent and oxygen concentrations with greater accuracy than manual adjustments.
v
End-tidal Control supports low-flow anesthesia, which may help reduce the amount of anesthetic agent utilized and potentially lower greenhouse gas emissions and costs.
vi
“Our team wanted to understand not only if End-tidal Control would be chosen for use in routine practice, but also how its use was associated with anesthesia delivery and environmental measures across a large academic health system,” said Douglas A. Colquhoun, MB ChB, MSc, MPH, Associate Professor of Anesthesiology at the
University of Michigan
vii
. “These findings suggest that End-tidal Control had a high adoption rate and, when used in real-world practice by anesthesia clinical teams it could translate to significant reductions in fresh gas flow resulting in projected cost saving and benefits for the environment.”
The study also found variation in End-tidal Control use was significantly driven by the in-room anesthesia clinician, underscoring the importance of workflow, education and implementation considerations when deploying anesthesia technologies at scale.
GE HealthCare
designs anesthesia solutions to support care that can help clinicians think one step ahead. End-tidal Control software can be used with the Aisys™ CS
2
anesthesia delivery system to enhance perioperative care.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Pharmaceutical Diagnostics and Patient Care Solutions segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.
GE HealthCare is proud to be among
2026
Fortune
World’s Most Admired Companies™.
Follow us on
LinkedIn
,
Facebook
,
Instagram
, or visit our website for our
latest news
and
perspectives
.
____________________
i
End-tidal Control in
the United States
is indicated for patients 18 years of age and older.
ii
GE HealthCare Et Control Pivotal Study Report DOC2163005
iii
Refer to the anesthetic agent labeling for information regarding indications for use, warnings, and other relevant clinical information specific to that anesthetic agent. For example, labeling for sevoflurane includes specific warnings related to the potential risk associated with use at a low flow rate and under certain clinical conditions. Any decisions regarding selection of anesthetic agent and flow rate should be made at the discretion of the clinician and in their medical judgment based on available information.
iv
Partial funding for data extraction and analysis related to this study was provided by
GE Healthcare
to the
University of Michigan
. The study protocol and statistical analysis plan were reviewed and approved a priori by the
University of Michigan
,
Department of Anesthesiology
, Anesthesia Clinical Research Committee.
v
McCabe MD, Dear GL, Klopman MA, Garg K, Seering MS. End-Tidal Control Versus Manual Control of Inhalational Anesthesia Delivery: A Randomized Controlled Noninferiority Trial. Anesth Analg. 2024
Oct 1
;139(4):812-820.
https://journals.lww.com/anesthesia-analgesia/fulltext/2024/10000/end_tidal_control_versus_manual_control_of.17.aspx
. doi: 10.1213/ANE.0000000000007132. Epub 2024 Jul 19.
vi
Tay, S., Weinberg, L., Peyton, P., Story, D., and Briedis, J. 2013. “Financial and Environmental Costs of Manual versus Automated Control of End-Tidal Gas Concentrations.”
Anaesthesia and Intensive Care
41 (1): 95–101.
https://journals.sagepub.com/doi/10.1177/0310057X1304100116
. doi:10.1177/0310057X1304100116
vii
The views expressed are solely those of Dr.
Douglas Colquhoun
, do not reflect the opinions or beliefs of
University of Michigan
and are based on his own opinions and on results that were achieved in the trial. Since there is no “typical” hospital/clinical setting and many variables exist, i.e. hospital size, case mix, staff expertise, etc. there can be no guarantee that others will achieve the same results.
View source version on
businesswire.com
:
https://www.businesswire.com/news/home/20261016050569/en/
GE HealthCare Media Contact:
Jennifer Purdue
M +1 267 593 9735
jennifer.purdue@gehealthcare.com
Source:
GE HealthCare